ニュース

The Commercial Life of a Drug Molecule A new drug’s commercial life is bounded by its patent estate. The composition of matter patent, which covers the chemical structure of the active ingredient, is typically the most valuable piece of IP and is usually filed at or near the time of initial synthesis. By the time […]

Why Solid Form Characterisation Starts with XRPD X-ray powder diffraction (XRPD) is the most widely used technique for characterising the crystalline structure of pharmaceutical solids. Every crystalline form of a drug substance produces a unique diffraction pattern, a fingerprint determined by the arrangement of molecules in the crystal lattice. This fingerprint allows scientists to identify […]

CMC Strategy Is Not a Static Document There is a common misconception in early drug development that CMC strategy means writing a dossier. It does not. CMC strategy means making deliberate decisions, at every stage of development, about which data to generate, which manufacturing processes to lock, and how to position the product for the […]

The Stability Trade-Off at the Heart of ASD Formulation The physicochemical advantage of an amorphous solid dispersion is real and well-documented. By eliminating the crystal lattice energy barrier, amorphous forms dissolve faster and achieve higher apparent solubility in biological fluids. For BCS Class II molecules with poor oral bioavailability, this translates directly into better clinical […]

Why CMC Filings Slow Programmes Down The Common Technical Document (CTD) format is used for regulatory submissions across the major pharmaceutical markets. Module 3, the Quality section, contains the chemistry, manufacturing, and controls data for both the drug substance and the drug product. It is the section that drug developers frequently underestimate in terms of […]

The Solubility Problem in Modern Drug Development Estimates from published literature suggest that more than 70% of new chemical entities in development pipelines have poor aqueous solubility. Many of these fall into BCS Class II (low solubility, high permeability) or Class IV (low solubility, low permeability) under the Biopharmaceutics Classification System. For these molecules, getting […]

Two Strategies for the Same Problem Poor aqueous solubility is one of the most common challenges in small molecule drug development. A molecule that does not dissolve adequately in the gastrointestinal fluid cannot be absorbed at a rate sufficient to achieve the intended therapeutic effect, regardless of how potent it is in a biochemical assay. […]

Why the First Crystal Form Is Rarely the Right One When a medicinal chemist synthesises a new active pharmaceutical ingredient for the first time, the crystal form that precipitates out of solution is a function of the solvent system, the temperature, and the rate of crystallisation used. It is rarely the thermodynamically stable form, and […]

Rare Disease Development Is a Different Kind of Problem The clinical supply challenges in rare disease drug development are categorically different from those in standard pharmaceutical programmes. Patient populations are small, sometimes in the dozens rather than the thousands. The drug may be highly potent, genetically targeted, or manufactured using a technology platform with limited […]

The Industry’s Environmental Challenge Pharmaceutical manufacturing is resource intensive. Organic synthesis generates solvent waste. GMP facilities consume significant energy for temperature and humidity control. Global clinical supply chains generate carbon through international shipping. For an industry that exists to improve human health, the environmental cost of drug production is an increasingly visible contradiction. This tension […]

Why the Geography of Your CDMO Partner Matters The choice to develop a drug in Europe rather than the United States is not just a matter of geography. It affects your regulatory strategy, your manufacturing standards, the reference points in your CMC dossier, and ultimately the timeline to your first clinical data. For many biotech […]

Where Outsourced Programmes Actually Go Wrong In a post-mortem analysis of delayed pharmaceutical development programmes, the root cause is rarely technical. It is almost always communication. The formulation team changed the API particle size specification but did not formally notify the manufacturing team. The client expected a stability report in a format that the CDMO […]